Telisotuzumab Adizutecan (NCT06820463)

Name: Telisotuzumab Adizutecan trial for Metastatic Colorectal Cancer (NCT06820463)
Uploaded: 2026-10-31T05:22:23.406Z
Duration: 1 min 16 s
Description: Telisotuzumab Adizutecan trial for Metastatic Colorectal Cancer (NCT06820463). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06820463.

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer: a one-minute explainerNCT068204631 min

Telisotuzumab Adizutecan trial for Metastatic Colorectal Cancer (NCT06820463). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with measurable metastatic colorectal cancer. Previous systemic c-Met-targeted drugs or topoisomerase inhibitors, including irinotecan, exclude participation.

The idea: telisotuzumab adizutecan delivers a toxic payload to c-Met-bearing cells. One substudy compares FOLFOX chemotherapy and bevacizumab with or without it. Another combines it with fluorouracil, leucovorin and panitumumab, compared with FOLFOX plus panitumumab. Dose escalation precedes randomized dose comparisons. Researchers measure response and safety.

This phase 2 study plans 390 patients. AbbVie sponsors it; 17 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.